Podcasts Health & Fitness Medicine NEJM Interviews NEJM Interview: Dr. Gil Rabinovici on the FDAs controversial approval of a new treatment for Alzheimers disease.

NEJM Interview: Dr. Gil Rabinovici on the FDAs controversial approval of a new treatment for Alzheimers disease.

Published: Aug. 25, 2021, 3:01 p.m.

b'Dr. Gil Rabinovici is a professor of neurology at the University of California, San Francisco. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. G.D. Rabinovici. Controversy and Progress in Alzheimer\\u2019s Disease \\u2014 FDA Approval of Aducanumab. N Engl J Med 2021;385:771-774. G.C. Alexander and Others. Revisiting FDA Approval of Aducanumab. N Engl J Med 2021;385:769-771.'